hCD40/h4-1BB(2)
品系全名
C57BL/6JSmo-Cd40tm1(hCD40)Tnfrsf9tm2(TNFRSF9)Smoc
目录号
NM-HU-200256
品系状态
胚胎冻存
品系描述
验证数据
图1 CD40&4-1BB双人源化小鼠 MC38 荷瘤模型体内抗肿瘤药效验证。CD40&4-1BB双人源化纯合子小鼠接种B16F10细胞系，肿瘤生长至约80mm3 时，随机将动物分组为对照组和不同组合的治疗组（n=6）。
结果显示：针对人源CD40的selicrelumab抗体和针对人源4-1BB的urelumab 抗体联合使用，有非常显著的抗肿瘤效果，证明CD40&4-1BB-HU 双人源化小鼠是一个很好的验证针对人CD40&4-1BB-HU 抗体联合药效的体内模型。
你也可能感兴趣
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
